The TriValve is a multicenter, international and retrospective study of multiple devices for percutaneous intervention to treat cardiac failure. This is a sub-analysis of patients receiving the most conventional of these devices: the MitraClip.
The main points assessed by this study were all cause mortality, unplanned hospitalizations, functional class, the presence of peripheral edema, and tricuspid regurgitation grade.
It included 249 patients, mean age was 77±9, and most (73.8%) presented atrial fibrillation.
Mean number of clips used was 2±1 with antero-septal localization in 65.1%, postero-septal 20.9% and other 14%. Reduction of tricuspid regurgitation ≥1 in 89.2% and more than half had concomitant mitral regurgitation treatment.
77% of patients were discharged with tricuspid regurgitation grade 1 or 2, which confirmed procedural success.
Peripheral edema was reduced from 84% to 26% at follow up.
Upon procedural failure, patients were followed up for mortality and rehospitalization rates.
Original title: TriValve: Evaluation of Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation.
Presenter: Jörg Hausleiter.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.